`
`llllllllllllllllllll
`
`ORIGINAL SUBNHSSION
`
`000003
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`..
`
`.
`
`-....,...o,».....~...g....... .. v-\.....-.«u..-..«-..~....\... p.\. .......x.......... .. _......,...,....*...,,....,..,..........
`
`.
`
`.
`
`CONSULTING GROUP
`
`Specializingin FDA RegulatoryMatters
`
`1))‘ f9~’ '/ Ff‘? 59 RCVD
`
`May 26, 2007
`
`Office of Food Additive Safety (HF S-255)
`Center for Food Safety and Applied Nutrition
`Food and Drug Administration
`5100 Paint Branch Parkway
`College Park, MD 20740-3835
`
`RE:
`
`Notification of GRAS Determination for Krill-based Lecithin in Food
`
`Dear Sir/Madame:
`
`In accordance with proposed 21 CFR § 170.36 (Notice of a claim for exemption based on a
`GRAS determination) published in the Federal Register (62 FR 18939-18964), I am submitting
`in triplicate, as the agent to the notifier, Enzymotec, a GRAS Notification for krill-based lecithin
`under the conditions of its intended use in food.
`'
`I
`
`ll"-'
`
`Please let me k.now if you have any questions.
`
`Sincerelv,
`
`Edward A. Stélele
`President
`
`Enclosures
`
`EAS Consulting Group. LLC
`1940 Duke Street, Suite 200, Alexandria, Virginia 22314
`(877) 327-9808 Toll Free 0 (703) 684-4408 Local - (703) 684-4428 Fax
`
`.
`
`00000 4
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`CONSULTING GROUP A
`
`""“
`
`Specializingin FDA RegulatoryMatters
`
`-g izegirir/‘rs:
`J
`MAY 2 9 my ,'
`
`BY: ________________ __
`
`I
`
`A.
`
`GRAS Exemption Claim '
`
`Claim of Exemption From the Requirement for Premarket Approval Pursuant to
`Proposed 21 CFR§170.36(c)(1) [62 FR 18938 (17 April 1997)]
`
`Krill—based lecithin has been determined to be Generally Recognized As Safe (GRAS),
`consistent with Section 201(5) of the Federal Food, Drug, and Cosmetic Act. This determination
`is based on scientific procedures as described in the following sections, under the conditions of
`its intended use in food. Therefore, the use of krill-based lecithin in food, as described below, is
`exempt from the requirement of premarket approval.
`
`Signed,
`
`
`
`/
`
`_u
`
`__«>’flZ<L_____
`
`\_,
`
`Edward A. Steele
`
`Date
`
`Agent for:
`
`Enzymotec, Ltd
`P.O. Box 6, Migdal HaEmeq
`Israel 23106
`
`Krill-based lecithin GRAS notification
`
`1
`
`'
`
`EAS Consulting Group, LLC
`1940 Duke Street, Suite 200, Alexandria, Virginia 22314
`(877) 327-9808 Toll Free 0 (703) 684-4408 Local - (703) 684-4428 Fax
`
`NEPN 2010
`
`S
`
`NEPN 2010
`
`
`
`..
`
`.
`
`.
`
`.
`
`i--........-4».«-.-.~..r..--..~. ...,..-.....,,...—..._....—«o-—wm«»«—.:»-..~.uua.».a.»-~.w~.«
`
`B.
`
`. Name and Address of Notifier
`
`Ms. Iris Meiri-Bendek
`
`Regulatory Affairs Manager
`Enzymotec, Ltd
`P.O. Box 6, Migda1HaEmeq
`Israel 23106
`
`C.
`
`Common Name of the Notifi d Substance
`
`The substance is commonly known as lecithin. Commercial lecithin is a complex mixture
`obtained from edible food sources that is characterized by the principle component phosphatidyl
`choline. The composition of both the phosphatidyl choline and the lecithin mixture may vary
`depending on the source from which it is obtained, as described below. Because the fatty acid
`composition of marine-derived substances differs from that of plants in a way significant for
`nutrition, a unique name is appropriate. In this notice, we are describing the product as krill~
`based lecithin although we have described it in previous correspondence as marine-derived
`phosphatidyl choline, or MD—PC.
`
`D.
`
`Conditions of Intended Use in Food
`
`The lecithin derived from krill is intended for use as a nutrient in those foods, at levels listed
`below in Table I, that do not contain other significant sources of docosahexaenoic acid (DHA)
`or eicosapentaenoic acid (EPA) as ingredients.
`
`Krill-based lecithin GRAS notification
`
`2
`
`000006
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`‘ Table I
`
`% Krill—based Lecithin
`Food
`
`
`Breakfast bars
`
`3.8
`
`Dairy product analogs (soy products)
`
`0.6
`
`Fat spreads
`
`Milk~based beverages
`
`Yogurt
`
`10.0
`
`0.6
`
`0.7
`
`3.3
`'
`Soft candy
`
`
`Va
`
`E.
`
`Basis for the GRAS Determination
`
`Pursuant to 21 CFR § 170.30, krill-based lecithin has been determined to be GRAS on the basis
`of scientific procedures.
`
`F.
`
`Availability of Information
`
`The data and information that serve as the basis for this GRAS Notification will be sent to the
`U.S. Food and Drug Administration (FDA) upon request, or will be available for review and
`copying at reasonable times at the offices of:
`
`Ms. Iris Meiri-Bendek
`
`Regulatory Affairs Manager
`Enzymotec, Ltd
`PO. Box 6, Migdal HaEmeq
`Israel 23 106
`
`Krill-based lecithin GRAS notification
`
`'
`
`3
`
`00000’?
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`Should the U.S. Food and Drug Administration (FDA) have any questions or additional \
`information requests regarding this notification, Enzymotec, Ltd. will supply these data and
`information.
`
`II.
`
`Detailed Information About the Identity of the Substance
`
`A. Identity
`
`Chemical or common names
`
`Phosphatidylcholine
`
`1, 2-diacyl-sn-glycero-3-phosphocholine
`
`Lecithin
`
`Structure of Phosphatidylcholine
`
`Phosphatidylcholine is a phospholipid that is a major constituent of cell membranes. More than
`90% of bile phospholipids are represented by phosphatidylcholine. Phosphatidylcholine is also
`known as, PtdCho and lecithin. It is represented by the chemical structure in Figure l:
`
`O
`
`0
`
`R1
`
`/[L R and R1 = fatty acids residues
`Ox/K/°~«,f{:*°\/\N+[CH }3 3
`ll
`
`ii
`
`7?
`
`Figure 1. Phosphatidylcholine
`
`The term lecithin itself has different meanings when used in chemistry and biochemistry than
`when used commercially. Chemically, lecithin is phosphatidylcholine. Commercially, the term
`lecithin refers to a natural mixture of neutral and polar lipids containing a large fraction of
`
`Krill-based lecithin GRAS notification
`
`4
`
`000008
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`phosphatidylcholine. Lecithin is naturally consumed through a diet containing lecithin rich
`foods such as egg yolk, soybeans, grains, wheat germ, fish, legumes, yeast, and peanuts, to name
`a few examples.
`__
`N
`_.
`
`Phosphatidylcholine, which is a relatively polar lipid, is present in commercial lecithin at
`concentrations ranging from 20 to 90%. Soybean, sunflower and rapeseed are the major plant
`sources of commercial lecithin with soybeans as the most common source. Plant lecithins are
`GRAS (generally recognized as safe) for use in food with no limitation other than current good
`manufacturing practice (21 CFR 184.1400). The fatty acid substituents on R and R1 positions of
`phosphatidylcholine from plant and animal sources differ. The R‘ second or middle carbon of
`the phospholipid molecule is mainly occupied by unsaturated fatty acids.
`
`Lecithin from krill is produced in two grades, A & B, differing in the purification level of the
`phosphatidylcholine. In lecithin derived from krill, the combined DHA (docosahexaenoic acid)
`and EPA (eicosapentaenoic acid) content is approximately 14-18% for Grade A and 20-25% for
`Grade B.
`
`Attached in Appendix A is a comparison of the Enzymotec krill-based lecithin products for both
`Grades A and B to the phospholipid content of commercial soy lecithin (Table A-1) and a
`comparison of the fatty acid content of commercial lecithin and menhaden oil to Grades A and B
`(Table A-2). As the comparison of soy- and krill-based lecithin products shows, the overall
`compositions are essentially the same except for the fatty acids, which reflect the different
`sources. The phospholipid composition shown in Table A-1 is very similar for the other two
`sources of lecithin. The fatty acid composition of Grades A and B is similar to that of menhaden
`oil and differs from soybean lecithin fatty acid composition in having notable amounts of the
`omega-3 fatty acids, particularly EPA and DHA, as expected.
`
`I Product Specifications
`
`Table II — Krill-based lecithin specifications
`
`Parameter
`
`Grade A
`Specification
`
`Grade B
`Specification
`
`Total phospholipids (%w/w)
`
`40-50
`
`PV (meq/Kg)
`
`Moisture (%)
`
`<5.0
`
`<3.0
`
`70-95
`
`<5.0
`
`<3.0
`
`Lead, cadmium, mercgy
`
`<lp_pm
`
`<lppm
`
`Knll-based lecithin .GRAS notification
`
`I
`
`5
`
`000009
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`B. Method of Manufacture and Compositional Analysis
`
`The source for this lecithin will be krill, which are tiny, free~swimming, shrimp-like crustaceans
`(euphausiids), which exist in large numbers in the open sea, mainly near Antarctica. The raw ‘
`material to be extracted, krill meal, is a biomass composed of lipids, sugars and proteins. By
`using a solvent extraction process, the proteins and free sugars are removed so that only lipids
`are left. Various solvents may be used for the extraction process, all of which are of food-grade
`quality and are used and removed from the product in accordance with current good
`manufacturing practice. The resulting extract, Krill-based lecithin Grade A may be further
`processed to enrich the phospholipid fraction and obtain Grade B (see Figure 2).
`Food grade antioxidants are added to the products in accordance with good manufacturing
`practice.
`
`Table B-1 contains compositional data of several batches per each grade. Grade A includes
`phospholipids, neutral lipids and other lipids (e. g. glycolipids), while Grade B includes almost
`exclusively phospholipids, almost no neutral lipids and about 8-10% of "other" lipids. The
`“Other lipids” were calculated through subtraction of the total phospholipids and total neutral
`lipids from the total lipids. As indicated by the toluene and hexane insoluble analyses, the
`product does not include protein or free sugars. Table B-2 provides the main fatty acid
`composition for total product Grades A and B, as % fatty acids of the product (by mass) and the
`fatty acid composition of the phospholipids and the phosphatidylcholine.
`
`/r
`‘Kw
`
`,
`'\..«
`
`_ Krill-based lecithin GRAS notification
`
`A6
`
`000010
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`Figure 2. Krill-based lecithin——Manufacturing Process Diagram
`
`Phospholiprd
`enrichment-
`
`
`
`
`
`,4- .
`
`Krill-based lecithin GRAS notification
`
`000011
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`C. Intended use
`
`Krill-based lecithin is intended for addition to a limited number of conventional foods as a
`nutritional ingredient. It is intended for the general population at the levels identified in Table I
`to dairy products (milk drinks and yogurt types), soy products, spreads, breakfast bars, and soft
`candy. We recognize that there are Standard of Identity requirements for some of these proposed
`foods and do not intend to refer to them by the commonly recognized names such as milk,
`chocolate or yogurt.
`
`D. Levels of Addition
`
`The maximum levels of addition as shown in Table I are calculated so as not to exceed the upper
`limit of 3 g/day of DHA and EPA as outlined in the menhaden oil regulation. Use is limited to
`food groups already described in 21 CFR 184.1472 (with breakfast bars considered as a cereal
`substitute) where no other significant source of DHA or EPA is added. Thus, krill-based lecithin
`will not add any DHA or EPA to food above that which is already permitted.
`
`E. Safety Assessment of Lecithin from Krill
`
`It is well established and recognized that phosphatidylcholine (lecithin) from either plant or
`animal sources is handled the same metabolically. Lecithin is absorbed into the mucosal cells of
`the small intestine, mainly in the duodenum and upper jejunum, following digestion by the
`pancreatic enzyme phospholipase A2 (Arnesjo et al., 1969; Belleville and Clement, 1969), by
`which the fatty acids in the 2 position are hydrolyzed to form lysophosphatidylcholine
`(lysolecithin) (Nieuwenhuizen et al. , 1974). Following absorption by the enterocytes,
`reacylation of lysolecithin takes place in these intestinal mucosal cells, reforming
`phosphatidylcholine,"while the previously released fatty acids can be further used for triglyceride
`synthesis (Tso and Fujimoto, 1994). Phosphatidylcholine is then transported‘ by the lymphatic
`system in the form of chylomicrons to the blood and metabolized by peripheral tissues. After the
`liver takes up the chylomicron remnants, the lipids are repackaged and secreted in the very low
`density lipoproteins (VLDL) (Ginsberg, 1998; Kang and Davis, 2000). Phosphatidylcholine is
`also incorporated into cell membranes, particularly in the lung. Phosphatidylcholine is also
`metabolized to choline, fatty -acids and glycerol. The fatty acids and glycerol are either oxidized
`to produce energy or become involved in lipogenesis. Choline serves as a precursor of the
`neurotransmitter acetylcholine and serum choline levels have been shown to peak between 2 to 6
`hours after oral intake of phosphatidylcholine.
`
`Krill-based lecithin GRAS notification
`
`.
`
`8
`
`000012
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`One possible basis for the biological actions of phosphatidylcholine administered orally is that
`the fatty acid from the 2 position is being utilized for either (a) triglyceride synthesis during the
`course of lipid absorption in the small intestinal epithelial cells; (b) for the formation of
`phosphatidylcholine for membranes in the small intestinal epithelial cells; or (c) used by other
`organs in the body. The fatty acids of phosphatidylcholine are shuffled to suit the needs of the
`cell as they change over time, or as the phosphatidylcholine "parent molecule“ is transported
`from tissue to tissue, cell to cell, or perhaps even from spot to spot within a membrane. Enzymes
`(hydrolases, acyltransferases) that remove or replace (re-esterify) fatty acids at position 2 of
`phosphatidylcholine are found in the intestinal epithelial cells, the hepatocytes, and other cells of
`the body. Phosphatidylcholine is also produced endogenously; for example, the liver secretes
`between 15-20 grams of phospholipids into the intestinal lumen and, of that, over 90% is
`phosphatidylcholine (Tso et al , 1977).
`
`In summary, there is no reason to believe, given the metabolic sequelae described above, that the
`marine-derived phosphatidylcholine and associated lipids normally present in marine organisms
`would pose any different health hazards than plant oil-derived lecithins and lipids except,
`possibly, for differences in lipid content based on the marine origin or possible contaminants
`from such a source. The following will discuss the consequences of increased consumption of
`DHA and EPA resulting from krill-based lecithin, and the possible presence of source-based
`contaminants.
`
`Recognizing that FDA has supplied tables of concentrations of menhaden oil in various foods
`consistent with safe levels of DHA and EPA, comparison of EPA + DHA concentrations in those
`foods from menhaden oil and krill-based lecithin may be done directly. In doing so, we are
`using FDA’s statement in the response letter to GRN 000109 that menhaden oil contains 8%
`DHA and 14% EPA.’ .Enzymotec concludes that the addition of krill-based lecithin to a small
`group of foods, other than baby foods, is GRAS at a level of approximately 1.5 gram per serving,
`which translates into a concentration that can be compared to that of menhaden oil, as described
`in the menhaden oil regulation. These levels are displayed in Table III. Because Enzymotec’s
`lecithin is produced in two grades, and because Grade B has a higher concentration of DHA and
`EPA, we will use Grade B as an upper limit scenario. The average composition of DHA and
`EPA in Grade B lecithin is 7.5% and 14.7 %, respectively. Coincidentally, this total of 22.2 % is
`essentially the same as that given by FDA (22%) for menhaden oil. Thus, we will compare
`concentrations of krill-based iecithin in foods with that of menhaden oil (see Table III). Grade A
`is approximately 16% DHA + EPA so that will produce less DHA and EPA in the diet when
`added at 1.5 g/serving. Serving sizes are taken from reference amounts in 21 CFR 101.12.
`
`Knll-based lecithin GRAS notification
`
`9
`
`000013
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`.- ~.-......
`
`Table III
`
`Concentrations of Krill-based Lecithin and Menhaden Oil as stated in 21 CFR 184.1472
`
`Food
`
`% Menhaden
`% Krill—based
`Reference amount (21
`CFR 101.12)
`lecithin
`Oil
`
`
`Breakfast bars
`
`40 g
`
`Dairy product analogs (soy Not listed; milk-based
`products)
`drinks = 240 g
`
`Fat spreads
`
`15 ml; ~15 g
`
`Milk—based beverages
`
`240 g
`
`Yogurt
`
`225 g
`
`3.8
`
`0.6
`
`10.0
`
`0.6
`
`0.7
`
`5.0
`
`‘
`
`Fats and oils
`12.0
`
`Milk products
`5.0
`
`Milk Products
`5.0
`
`4.0
`3.3
`45 g
`Sofi candy
`
`
`The menhaden oil rule permits several additional applications where krill-based lecithin would
`not be used. The important point is that in all applications where either lecithin or menhaden oil
`might be used, the levels of lecithin (and subsequent levels of DHA+EPA) are lower than what is
`allowed from menhaden oil, sometimes much less. We agree with the limitation that krill-based
`lecithin not be used with other ingredients that are good sources of DHA or EPA; thus it will not
`be added to foods containing other significant sources of DHA or EPA as ingredients. The one
`food category discussed for krill-based lecithin that is not the subject of the menhaden oil rule is .
`- breakfast bars. However, these would generally substitute for cereals, which are allowed by the
`menhaden oil rule. According to 21 CFR 101.12, reference amounts for cereals range from 15 -
`55 g. At a concentration of menhaden oil of 40%, this would range from 0.6 to 2.2 g menhaden
`oil. Therefore, the use of krill-based lecithin in breakfast bars would simply substitute for
`breakfast cereals at a level lower than that allowed for menhaden oil. We also note that dairy
`product analogs (soy products) can come in a variety of forms such as “soy milk” or yogurt
`substitute. The important thing is that these would replace milk-based products already
`permitted in 184.1472.
`.
`
`In sum, the use of krill-based lecithin in foods, as intended by Enzymotec, would contribute far
`less DHA + EPA than what is currently authorized from use of menhaden oil in these foods, as
`Krill-based lecithin GRAS notification
`
`10
`
`000014
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`-v -- v
`
`-—.. -M». .4 ovrswmvv %«rw~_m~m~«m«m»w
`
`listed in 184.1472, or other fish oils subject to GRAS notifications. Importantly, it does not
`contribute to any increase in cumulative DHA + EPA intake because krill-based lecithin would
`simply provide equal or less of these fatty acids than that which has already been considered for
`these foods and concluded to be safe. While use may broaden the range of products with these
`fatty acids from which a consumer may choose, such products would simply provide alternative
`products to those that are currently permitted and would not add to the current cumulative intake
`for users of such products.
`
`A second consideration is whether contaminants that might be stored in marine lipids could pose
`a risk to health. Krill have been a significant food for higher marine species and have presented
`no safety concern. Importantly, krill are very low on the food chain and would not
`bioaccumulate lipid-soluble contaminants as occurs in larger species. Nevertheless, because this
`ingredient is from the lipid fraction, we have conducted analyses for likely contaminants on two
`batches as found in Table C-l in Appendix C. Because Grade B is made from Grade A, a simple
`calculation was performed using the exaggerated assumption that all of each contaminant would
`stay with the lecithin throughout the purification step and, thus, be concentrated by 2.5 times in
`the Grade B as compared to Grade A. This, of course, is unlikely but provides an upper—bound
`estimate. As seen, the levels are low and consistent with levels in other food ingredients.
`
`Finally, krill, being a crustacean, could contain protein that might be allergenic to individuals
`allergic to certain crustaceans. However, the processing of the lipid fraction should reduce
`proteins to a negligible level. Nevertheless, based on the requirements of the Food Allergen
`Labeling and Consumer Protection Act of 2004, the word “krill” will appear in the ingredient list
`unless it can be shown that no protein is present; a successful notification is filed demonstrating
`no allergenic protein; or a successful petition is filed demonstrating that the ingredient does not
`cause an allergic response that could pose a risk to human health.
`
`III. CONCLUSIONS
`
`In sum, based on the information provided above and the fact that the constituents of krill-based
`lecithin are commonly found in food, and because these lipids and phospholipids are essentially
`the same, and will be handled metabolically the same as those derived from plants, we conclude
`that scientific experts, generally, would recognize them to be as safe and as acceptable as plant
`lecithin and lipids. Further, we believe that there are no significant questions regarding the .
`safety of krill-based lecithin that would appear to require additional safety studies, due to the
`prior consideration and acceptability by the Agency for plant-derived lecithin and other
`phospholipids and fish oil-derived omega-3 fatty acids.
`
`Krill-based lecithin GRAS notification
`
`11
`
`000015
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`References
`
`Amesjo B, Nilsson A, Barrowman J, Borgstrom B (1969) Intestina_l__digestion and absorption of
`cholesterol and lecithin in the human: Intubation studies with a fat-soluble reference substance.
`Scand J Gastroenterol. 4(8):653-665.
`
`Belleville J and Clement J (1960) Phospholipase A2 activity of extracts of pancreatic jiiice and
`pancreas from humans, rats and dogs. J Physiol (Paris). 61 Suppl 1:87.
`
`Ginsberg HN (1998) Lipoprotein physiology. Endocrinol Metab Clin North Am. 27(3):503-S l9.
`
`Kang S and Davis RA. (2000) Cholesterol and hepatic lipoprotein assembly and secretion.
`Biochim Biophys Acta. 1529(1—3):223—230.
`
`NAS IOM (National Academy of Sciences, Institute of Medicine) (1998) Dietary Reference
`Intakesfor Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid,
`Biotin, and Choline. National Academies of Science Press, Washington, D.C.
`
`Nieuwenhuizen W, Kunze H, de Haas GH (1974) Phospholipase A2 (phosphatide acylhydrolase,
`EC 3.1.1.4) from porcine pancreas. Methods Enzymol. 32(Pait B):147-154.
`
`\_,,
`
`Tso P, Balint JA, Simmonds WJ (1977) Role of biliary lecithin in lymphatic transport of fat.
`Gastroenterology. 73(6): 1362- 1 367.
`
`Tso P and Fujimoto K. (1991) The absorption and transport of lipids by the small intestine. Brain
`Res Bull. 27(3-4):477-482.
`
`Krill-based lecithin GRAS notification
`
`.
`
`12
`
`/.,
`
`\...«
`
`000016
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`vv~r— .
`
`.
`
`.. -. _..... » - .........—,..,......-.............-,.. -»..~.~*~»%
`
`\...r
`
`Appendix A:
`
`Typical phospholipid and fatty acid compositions of various lecithins
`
`Table A-l- Phospholipid composition
`
`Phospholipids
`Commercial
`Commercial
`Grade A
`Grade B
`Composition (%w/w)
`fluid soy
`High Grade Soy Krill- based Krill- based
`lecithin
`Lecithin
`Lecithin
`Lecithin
`
`
`Total
`'
`44
`88
`46
`75-95
`
`Phosphatidylcholine
`
`Phosphatidylethzinolamine _
`
`Phosphatidylinositol
`
`' Lysophosphatidylcholine
`
`35
`
`3
`
`1
`
`3
`
`’
`
`78
`
`4
`
`0.5
`
`2.5
`
`36
`
`3
`
`2
`
`2
`
`60-85
`
`0-7
`
`1-5
`
`3-9
`
`1-6
`3
`3
`2
`Others
`,«
`K.
`
`I
`K,
`
`Krill-based lecithin GRAS notification
`
`—
`
`13
`
`00001’?
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`-
`
`-
`
`.
`
`-
`
`-
`
`.
`
`«
`
`-
`
`- wuv«ww-mwwnm-wwwmmwagw-~«u »
`
`Table A-2 - Fatty acid composition
`
`Fatty Acid
`Soybean
`Menhaden
`Grade A**
`Grade B**
`Composition
`Lecithin*
`Oil*
`Krill-based
`Krill-based
`as % wlw of
`Lecithin
`Lecithin
`
`product
`22:6n3 (DHA)
`
`22:5n3
`
`22:1
`20:5n3 (EPA)
`
`A
`
`20:4
`
`20:1
`
`C18:4
`
`C18:3
`
`C18:2
`
`C18:1
`
`C18:0
`
`C16:1
`
`C16:0
`
`0.00
`
`0.00
`
`0.00
`0.00
`
`0.00
`
`0.00
`
`0.00
`
`5.14
`
`40.18
`
`10.57
`
`2.92
`
`0.40
`
`11.98
`
`8.56
`
`4.92
`
`0.35
`13.17
`
`1.17
`
`1.33
`
`2.74
`
`1.49
`
`2.15
`
`14.53
`
`3.78
`
`10.48,
`
`15.15
`
`5.3
`
`_
`10.3
`
`0.9
`
`1.5
`
`13.2
`
`0.9
`
`5.2
`
`15.1
`
`7.5
`
`14.7
`
`0.8
`
`2.3
`
`5.8
`
`0.7
`
`1.2
`
`13.0
`
`1.2
`'
`7.1
`7.96
`0.10
`C14:0
`
`* Source - The USDA National Nutrient Database for Standard Reference
`** Average fatty acid composition of main fatty acids
`
`KriIl—based lecithin GRAS notification
`
`14
`
`000018
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`Appendix B: K1-ill—based Lecithin -— Batch data
`
`Table B-1 — Product composition
`
`Grade‘A ‘"57
`Grade B
`
`
`Lipid composition
`
`
`Phosphoiivids
`(%w/w)
`
`Total
`
`44.2
`
`45.4
`
`47.3
`
`91 .8
`
`75.6
`
`89.2
`
`iatch
`
`Batch
`
`Batch
`
`Batch
`
`Batch
`
`Phosphatidyl
`choline (PC)
`Phosphatidyl
`ethanolamine (PE)
`Phosphatidylinosito
`1 (PI)
`Lysophosphatidyl
`choline (LPC)
`Others
`
`36.8
`
`37.3
`
`33.7
`
`82.5
`
`60.2
`
`65.1
`
`1.5
`
`0.8
`
`2.8
`
`2.3
`
`2.1
`
`1 .4
`
`2.8
`
`1.9
`
`'
`
`4.2
`
`»
`
`2.1
`
`1 .1
`
`6.3
`
`0.0
`
`1 .9
`
`6.4
`
`1.1
`
`2.1
`
`1 .9
`
`8.1
`
`3.4
`
`6.8 .
`
`4.1
`
`3.3
`
`5.3
`
`Total
`
`52.0
`
`50.0
`
`Neutral lipids
`(%w/w)
`
`Diglycerides
`
`19.8
`
`13.0
`
`Monoglycerides
`
`'[*rig1yce,-ides
`
`Free fatty acids
`
`Free cholesterol
`
`2.0
`
`25.3
`
`2-9
`
`ND
`
`Cholesterol esters
`
`20
`
`4.9
`
`25.3
`
`3-3
`
`1
`
`2-1
`
`47.3
`-
`
`13.6
`
`2.2
`
`25.6
`
`32
`
`1-4
`
`1-4
`
`ND
`
`ND
`
`ND
`
`ND
`
`ND
`
`ND
`
`ND
`
`ND
`
`ND
`
`0-8
`
`ND
`
`ND
`
`other lipids (e.g.
`glycolipids)
`
`(%w/w) *
`Toluene insoluble
`None
`None
`None
`
`3 .3
`
`4.5
`
`5.3
`
`8.0
`
`10.0
`
`Hexane insoluble
`I
`None
`None
`None
`
`
`"‘ calculated based on mass balance
`
`Krill-based lecithin GRAS notification
`
`-
`
`2
`
`A 15
`
`000019
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`'--—v~
`
`........-..~-.
`
`-+-- ~o-.-V». ~—.—..-4......
`
`Appendix B continued: Krill Lecithin — batch data
`
`Table B-2 — fatty acid profile
`
`
`
`Grade A
`
`Grade B
`
`Batch
`Batch
`Batch
`Batch
`Batch
`Batch
`1 15.1‘
`
`
`
`Fatty acid profile (main fatty acids)
`
`As %w/w of the product
`
`DHA
`
`EPA
`
`C18:4 n3
`
`C18:2
`
`C18:1
`
`C18:0
`
`C16:1
`
`5.2
`
`10.7
`
`1.2
`
`1.1
`
`4.9
`
`9.7
`
`0.8
`
`1.3
`
`12.9
`
`13.5
`
`0.8
`
`5.3
`
`0.9
`
`5.5
`
`16.1
`
`5.3
`
`6.7
`
`6.5
`
`10.4
`
`15.4
`
`13.6
`
`0.6
`
`2.2
`
`13.1
`
`0.9
`
`4.8
`
`1.0
`
`2.5
`
`3.4
`
`0.5
`
`1.1
`
`0.7
`
`1.1
`
`5.9
`
`0.8
`
`1.3
`
`9.2
`
`15.2
`
`0.7
`
`3.3
`
`8.0
`
`0.8
`
`1.1
`
`14.7
`
`13.2
`
`12.0
`
`13.8
`
`8.2
`
`6.3
`
`1.2
`
`1.4
`
`1.1
`
`13.3
`
`11.2
`
`30.5
`
`25.4
`
`2.0
`
`5.8
`
`6.7
`
`1.0
`
`2.1
`
`1.4
`
`2.2
`
`1.3
`
`2.2
`
`12.2
`
`14.8
`
`C16:0
`
`Cl4:0
`
`As % of total fatty acids on Phosgholigids
`
`DHA
`
`EPA
`
`C18:4 n3
`
`C18:2
`
`Ci8:i
`
`C18:O
`
`C16:1
`
`C16:0
`
`C14:0
`
`14.4
`
`6.8
`
`14.0
`
`28.5
`
`1.8
`
`9‘<3
`
`~.1 C:
`
`25.0
`
`2.2
`
`Krill-based iecithin GRAS notification
`
`15.8
`
`26.4
`
`1.3
`
`5.7
`
`14.1
`
`1.5
`
`1.6
`
`12.2
`
`23.0
`
`1.4
`
`6.2
`
`1.5
`
`1.9
`
`25.6
`
`1.9
`
`16
`
`22.5
`
`26.0
`
`26.2
`
`1.5
`
`2.2
`
`2.3
`
`000020
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`»..-‘—n—..p...,
`
`. .. ..—...........,....,___ .,,,,\
`
`
`
`
`Grade A
`Grade B
`
`
`Batch
`Batch
`Batch
`Batch
`Batch
`Batch
`B
`3
`H g -
`
`o A
`
`s % of total fat_ty ac1ds on PC
`ADHA
`EPA
`
`CI8:4 n3
`C182
`
`C18:1
`
`c18:0
`
`C16:1
`
`C1620
`
`'
`13.2
`31.6
`
`1.7
`5.3
`
`6.8
`
`1.0
`
`2.0
`
`11.7
`27.9
`
`1.6
`2.9
`
`13.0
`
`1.3
`
`1.9
`
`24.0
`
`23.0
`
`.
`
`13.5
`32.1
`
`0.3
`1.1
`
`13.5
`
`1.0
`
`1.8
`
`22.9
`
`12.5 I
`30.6
`
`1.9
`5.2
`
`6.8
`
`1.0
`
`2.1
`
`12.0
`27.7
`
`1.5
`2.2
`
`13.7
`31.2
`
`03
`1.3
`
`11.3
`
`12.9
`
`1.1
`
`2.3
`
`1.2
`
`1.7
`
`25.0
`
`25.6
`
`22.2
`
`1.2
`2.4
`1.9
`1.5
`1.0
`1.7
`c14:0
`
`
`Kr1H-basediecnhtn GRAS notnficatuon
`
`17
`
`000021
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`~-~v-n+9.-V-vuw-urn n«u.-u-«-.—.-.-.-—...-.«.-.-g.-mg
`
`Appendix C: Chemical contaminants
`
`Table C-1
`
`
`Grade A
`
`Grade B (calculated
`values*)
`
`Batch
`Batch
`Batch
`Batch
`1 1 H1
`8.5 ppb
`2.1 ppb
`_<_2l.3 ppb ’
`
`PCBs — Total
`
`55.4 ppb
`
`PCBs -sum of
`28,52,10l,1l8,l38,153,l80
`Dioxins and Furans
`WHO TEQ with DLs
`Pesticides
`
`Heafl metals
`
`1.5 ppb
`
`0.3 ppb
`
`$3.7 ppb
`
`50.7 ppb
`
`1.6 ppt
`
`0.5 ppt
`
`$3.9 ppt
`
`51.3 ppt
`
`Non
`detected
`
`Non
`detected
`
`Total Arsenic
`
`3.6 ppm
`
`3.6 ppm
`
`59.0 ppm
`
`59.0 ppm
`
`Inorganic Arsenic
`
`Lead
`
`Mercury
`
`<0.005ppm Not
`measured
`<0.05 ppm
`
`<0.05 ppm
`
`<0.005ppm
`
`0.009ppm
`
`<0.0125
`ppm
`<0. 125 ppm <0.l25
`ppm
`
`<0.0l25
`Ppm
`
`50.0225
`Ppm
`
`<0.l25 ppm <0.125
`<0.05 ppm
`<0.05 ppm
`Cadmium
`
`ppm
`
`* Grade B is a 2.5 fold concentrate of Grade A, thus the worse case scenario for contaminants
`would be that all of them are carried over to Grade B and therefore the levels in Grade A would
`
`be multiplied by 2.5.
`
`Kr:II—based Iecrthm GRAS notification
`
`18
`
`000022
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`-on- arm-wN4-14 -r- .-v-—..«....a
`
`BatchE Dioxins and Furans
`
`W'ELLINGTON
`LABORATORIES
`
`345 Soulhgate Dnve
`Guelph ON N16 3M5 CANADA
`Tel 519-822-2436
`Fax 519-622-2849
`
`2008-481-ENZ
`
`
`Table A: Dloxmu and Funnu. OI
`
`
`
`
`
`
`
`
`
`
`
`.A°33
`
`IIIIIIHIIIIIIII
`
`Segtamggg 29, 2_§Q§
`D ta
`
`
`
`
`
`ZO '5 :3
`
`2 U '5 -V
`
`IIIIIIIIIIIIIIIIIIIII
`
`
`
`
`
`ND (0 1)
`
`ND (0 1
`
`—m
`
`am
`K)
`375»TCDF
`Total TCDF:
`T12378-PeCDF
`3478-PBCDF
`oral PGCDFS
`—{N
`—123478-Hxcnr
`. 123678-HXCDF
`234678—HxCDF
`123789— DF
`ND (0 1
`Total HxCDFs
`——
`1234676—HpCDF
`o 2
`1234789-Hpcor
`ND (0 1)
`Total Hpc DFs
`
`T——-
`——E3
`TM
`
`78-TCDD
`Total TCDDs
`
`
`
`12378-PeCDD
`Total PeCDDs
`—23478-Hxcno
`123678-HXCDD
`123789-HXCDD
`Total HXCDD5
`
`ND (0 1)
`ND (0 1)
`
`ND (0 1)
`O
`
`NU
`
`0 341 -z
`
`
`
`
`
`
`
`—1
`
`234678-HpC on
`Total HpCDDs
`_ocoo
`
`WHO TEQ (wnn DLs) ‘
`
`
`
`
`
`
`1135!}.
`-3331-
`—
`ND (0 1)
`ND (0 1)
`
`r«rIn—nasea leclmln UK/-\b HOIITICZIIOD
`
`IU
`
`000023
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`VVELLINGTON
`LABORATORIES
`
`345 Soulhgale Drive
`Guelph ON N1G 3M5 CANADA
`Tei 519-822-2436
`Fax 519—822-2849
`
`
`
` Z
`
`
`
`
` Z
`
` —jZ
`Tit
`
`'
`’;'..'_! C
`
`—§ij—i$
`——jZ
`136-1237&PoCDF
`59 ——iZ
`j-ij_j:j—i—
`
`——iZ
`jij—jj—j—
`—jij—j—
`—1:‘1—j—
`130-123478-Hxcoo ji—j§j—jC
`Tit
`1
`- 23678-HDCDFii
`— — —j—
`—jIi—iZ
`1'
`
`ckeisiTI
`—
`F:T j
` —
` $
` —
`2::---'-T
`
`5 MS‘ '
`I
`
`
`
`i
`
`Z
`
`Page 2
`
`Kril|—based lecithin GRAS notification
`
`20
`
`000024
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`no»-u-«.....—..-.-.-a-............-m
`
`
`
`jiij
`_1-_
`mi-
`—_
`—_i_
`—m
`—11—
`_m
`-11-
`E-
`—11—
`—1_
`“-
`—1_
`-- —_
`-‘H2-I-—X1‘
`—&%@H“—XX—
`1‘.'§4:Ij—11*
`“-11-
`1-“-
`11-11-
`-
`um-
`“-11-
`CW1-
`“-1--
`"W-
`C-—--—
`=
`1=—
`Z “XX-
`“X1
`1-“
`_ _-—l-
`-—1I
`-
`‘
`' fly
`—iJ.'_lLllZ1-——
`
`-_—_f
`
`l———f
`
`' If--11
`:
` !-—:
`' I--11
`'
`XE!-!j—1I
`jIL:Xj—1I
`' 11--
`——
`——
`—
`mi-
`—-_
`1--
`11-
`11-
`——
`-—
`
`l—-————_
`
`'-'-3%
`—-
`KHZ‘
`-
`—-
`-
`“II-
`1-“-
`Ij=_
`' 1-
`II-
`‘ ——
`C-
`' -
`I--§L'X&I.‘iIj_1I—
`'
`' _1_
`I " ‘ Cm-
`
`
`
`
`
`
`
`
`
`
`,
`
`
`_,
`_
`
`
`KnII—based lecathm GRAS notufncatnon
`
`21
`
`000025
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`airw-
`
`L_
`
`.w.p.
`
`ona - -' 3
`.
`r
`..
`
`.
`
`00
`
`O.
`
`.....
`
`..
`
`.3.
`I..-
`
`_._._._____.__..____Tau"-..u--..._r_u___“______m0__
`
`I L.
`I
`nnic ".
`
`I 0'!
`
`CI
`
`..,.-
`
`I.-
`
`
`
`___:-nmmuuummmuuu.
`
`-L.o.
`
`I I03‘
`
`-1‘-
`11:1
`-0
`-351-
`X121
`-1!-
`-52-
`11.51
`‘Z:
`
`‘[23:
`‘Pl’-
`-5!-
`—£-
`12-
`‘Si:
`-52.;
`j}-
`j?‘-
`-245;
`-311
`_I
`_-
`—I
`O
`
`.m_._.........mmm...%0__=====_=_=—
`
`..
`MK‘)!
`.
`
`\VU
`
`I--sci
`
`-
`
`
`
`..0Z.......o.lt.1.vo.
`
`II..3Sull
`
`'3 R0 69 " ECOI1 1111! In
`
`1-V: 3
`
`5..B
`
`in
`
`Krill-based lecithin GRAS notification
`
`22
`
`000026
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`
`
`
`
`
`
`-\--4'-v-—-Ir -xv-an--—~~m-m~
`
`Batch 80-63A — Pesticides
`
`WELLINGTON
`LABORATORIES
`
`2&2?‘-461-BN2
`
`_ __
`
`3-'15 Southgate Dnve
`Guelph ON N1G 3M5 CANADA
`,3; 3133:3333
`
`we
`
`a-CHLORDANE
`
`'
`
`t-NONACHLOR_
`
`—'.-lflilij
`
`
`—"
`
`°‘5 ~-~ _
`
`
`Knll-based lecithin GRAS notification
`
`'
`
`23
`
`00002’?
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`‘
`
`*
`
`~
`
`~
`
`\
`
`-
`
`~
`
`-v--on-— ~~- ~~vww~«»m:m—m
`
`Batch-— Dioxins and Furans
`
`WELLINGTON
`LABORATORIES
`
`345 Southgato Diwe
`Guelph ON N1G 3M5 CANADA
`Tel 519-822-2436
`Fax 519.322.2349
`
`
`
`
`
`
`
`
`
`‘ll
`
`Date
`
`
`
`IXII1I
`
`E!
`I33
`
`I-I
`I1
`
`EI
`
`III iIIIZZII
`
`ZI
`
`Z III- I
`
`ND(01
`ND(01) 1
`ND (0 1_L
`NDR(0 6) —
`ND (0 6) 1
`
`at
`
`iiisiiii L‘
`
`
`—
`Table A' DIOXIIII Ind Funiu: Olllppt)
`
`|“i||||||
`
`
`
`162-290
`
`Q N
`
`ND (0 1)
`A
`
`'
`
`ND (0 1) —
`I (O 1) -
`I
`— ND(D1)
`— NDR(O 3)
`- ND (0 3)
`-
`ND(01) —
`3 ND (0 1)
`— ND go 1;
`
`..
`
`O &
`ND (0 2
`
`NDR (0 5) E
`ND (0 1)
`ND (0 5) -
`1
`NDR(O9) — NDR(05)
`
`ND(01)
`ND(01)
`
`78-TCDF
`ota CDF:
`
`..A
`
`2378-Pecor-'
`3478—PeCDF
`otai PeCDFs
`
`23478-H DF
`23578~HXCDF
`34678~HxCD
`789-HXCDF
`
`ola H F5
`1234678—HpCDF
`1234789-H CDF
`
`BE?N9,.3. U0
`
`ota ' CD03
`
`12378-PGCDD
`-4
`ma! PeCDDs
`
`478-Hx DD
`1
`123678-HXCDD
`
`ota ‘ XCDDS
`4675-HDCDD
`"eta HPC DDs
`
`lllliliiliélil
`
`WHO TEQ (with DLs
`
`
`
`
`
`
`
`ND (0 1)
`‘ I
`I
`
`ND(O1)
`
`ND(O1)
`N (
`NR(0 7)
`
`:_
`—I
`
`o 348 pt
`
` n
`
`Page 1
`
`Krill-based lecithin GRAS notification
`
`'
`
`24
`
`000028
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`LARORATORIES
`
`345 Southgale Dave
`Guelph ON N1G 3M5 CANADA
`Tel 519-822-2436
`
`
`
`
`' {IjI"""""
`-
`'
`—
`=
`——C—C—1
`—ZZEE~EjZOZ
`
`
`
`
`
`
`C=Z_C
`t
`103 - 78 _-
`13C~2376-TCDF
`$Z—Z
`90 11-1
`130-12378-PGCDF "
`13c-23473-PecoF W_
`13C-12375-PecDD
`68 -—-
`130-123478~HxC0F
`I 74 _
`0101-1
`0011-1
`-§ C—Z
`114 CZ—Z
`130423676-HXCDD ZOZ
`101-1
`13C~1234789-H 0'’ j2jCj§_Z—Z
`j Z130-0000
`j£—Zj§j_Z
`
`——Z—Z_Z
`
`___.___ 01
`ts)
`I
`ND . nsrectea (de! 8 m bracke
`NDR - none detected based on peak ratno -
`Nos - none detected based on peak shape -
`
`||||I!
`
`
`
`
`Page 2
`
`Knll-based lecxthm GRAS notification
`
`.
`
`25
`
`000029
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`‘IIllIll|||||IIIllllIll||||||||||||||ll|||l|ll|||
`
`
`IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIEilILIIIIIIII“IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII+ii
`
`
`11
`
`I
`
`j——j
`0—l-r-1a=rsr-1_——u.,ta:.&k1-J
`—.=i-_1_=:_tsxgL=_:=1u_=_t.:_w.——jm—j
`
`-3 =,
`- 5;
`
`3
`
`~
`
`‘o
`
`' =f
`
`‘
`
`= —I.|1.Jfl9I
`
`'
`
`,
`
`'
`
`——11$
`
`-
`
`-‘um'—'”
`
`«-
`
`|‘\flll-D8580 IBCIIUIH UK/'\D UOIITICHIIOH
`
`n
`40
`
`000030
`
`NEPN 2010
`
`NEPN 2010
`
`
`
`. u ... ...-.- ... arc--r»~v-cut
`
`375431!I
`
`
`.......mmu_umuuuuuj..........=............-,.......1H
`
`===__==_===_.====—_=___==.=_—_
`.......mmuuuuuuuuuu.............._..........._.......
`
`—-W-——-——--——-—--——-—---—-—-.
`
`
`4I
`
`I jj—
`
`:u—
`1m—
`—-n:—
`
`jj1
`
`2:
`-‘.1’:
`1.e—
`$4:
`-1::
`jag
`-12:
`—1m—
`-311
`
`E11:—:u:—
`
`-1.:
`-11:
`—:nb—
`-1:-x=.—
`-12:
`—1a::—
`mt;-L-—
`-11.-2—
`—j
`
`jj
`
`
`
`
`
`0....u--x....m.a....X..Qa
`
`———— ¢
`
`
`k'|i=l’i*J;‘.L¢J
`Edam!
`iZ{‘l'laI'
`1
`on - om- s
`n
`'
`I
`
`I .o
`
`.
`
`n
`oro- s
`.
`axe m- s
`or - oro- s
`O|'O-
`S
`o 3.
`one - I0
`I ca—c aro-
`
`:9
`
`.u.
`
`vv - g
`ll
`
`..‘vivwwtfvilfrn
`
`....._...........WWW..